Uploaded July 2026 | Updated November 2026, 4 days ago
Does your metabolism really crash at 40, and is your thyroid, your cortisol, your PCOS, or menopause the reason the scale will not move? This segment from our Calories in, Calories out episode takes the two most common excuses for weight gain, a broken metabolism and out-of-whack hormones, and tests each one against the best evidence we have. A 2021 Science study measured daily burn in more than 6,000 people with the gold-standard method and found it basically flat from age 20 to 60, with no cliff at 40. Real metabolic adaptation after weight loss is closer to 70 to 130 Calories a day than the 300 to 400 you have heard, and most of even that is more efficient movement, not your organs powering down.
On the hormone side: hypothyroid weight gain is mostly water, not fat, and treating it brings you back to about where you started. The biggest cortisol analysis, more than 26,000 people, puts its link to body size at about 1 percent, and the arrow may even point the other way. PCOS, now renamed PMOS, lowers burn per kilogram of lean tissue by about 10 percent, but total burn comes out about the same, and women with and without it lose the same weight on the same diet. Menopause itself adds only about a kilogram and a half of fat and mostly changes where it sits. Every one is real physiology, and not one of them breaks the equation. Each is a hand on a lever that moves how much you eat or how much you burn.
Timestamps:
0:00 The first claim: your metabolism is broken
0:21 No cliff at 40: the doubly labeled water study
1:31 How real is metabolic adaptation after weight loss
2:54 When the food diary takes the blame
3:47 Claim 2: it's my hormones
4:05 Thyroid: mostly water, not fat
5:33 Cortisol: about 1 percent of the difference
7:10 PCOS is now PMOS
9:04 Menopause and the pattern across every hormone
Resources
Barbell Medicine coaching and templates: barbellmedicine.com
Plus podcast subscription: barbellmedicine.com/shop/subscriptions/plus-podcast-subscription
Barbell Medicine Premium: barbellmedicine.com/shop/subscriptions/barbell-medicine-premium
Signal (book pre-order): barbellmedicine.com/shop/learning/signal
Metabolism
Pontzer et al., Science 2021. doi.org/10.1126/science.abe5017
Muller et al., American Journal of Clinical Nutrition 2015. doi.org/10.3945/ajcn.115.109173
Lichtman et al., New England Journal of Medicine 1992. doi.org/10.1056/NEJM199212313272701
Hormones
Karmisholt et al., Journal of Clinical Endocrinology and Metabolism 2011. doi.org/10.1210/jc.2010-1521
Lee et al., Endocrine Practice 2014. doi.org/10.4158/EP14072.OR
van der Valk et al., Obesity Reviews 2022. doi.org/10.1111/obr.13376
Nikokavoura et al., Diabetes, Metabolic Syndrome and Obesity 2015. doi.org/10.2147/DMSO.S85134
Greendale et al., JCI Insight 2019. doi.org/10.1172/jci.insight.124865
Also referenced: the PCOS-to-PMOS renaming (The Lancet consensus, 2026) and the American Thyroid Association patient guidance on thyroid weight.
Does your metabolism really crash at 40, and is your thyroid, your cortisol, your PCOS, or menopause the reason the scale will not move? This segment from our Calories in, Calories out episode takes the two most common excuses for weight gain, a broken metabolism and out-of-whack hormones, and tests each one against the best evidence we have. A 2021 Science study measured daily burn in more than 6,000 people with the gold-standard method and found it basically flat from age 20 to 60, with no cliff at 40. Real metabolic adaptation after weight loss is closer to 70 to 130 Calories a day than the 300 to 400 you have heard, and most of even that is more efficient movement, not your organs powering down.
On the hormone side: hypothyroid weight gain is mostly water, not fat, and treating it brings you back to about where you started. The biggest cortisol analysis, more than 26,000 people, puts its link to body size at about 1 percent, and the arrow may even point the other way. PCOS, now renamed PMOS, lowers burn per kilogram of lean tissue by about 10 percent, but total burn comes out about the same, and women with and without it lose the same weight on the same diet. Menopause itself adds only about a kilogram and a half of fat and mostly changes where it sits. Every one is real physiology, and not one of them breaks the equation. Each is a hand on a lever that moves how much you eat or how much you burn.
Timestamps:
0:00 The first claim: your metabolism is broken
0:21 No cliff at 40: the doubly labeled water study
1:31 How real is metabolic adaptation after weight loss
2:54 When the food diary takes the blame
3:47 Claim 2: it's my hormones
4:05 Thyroid: mostly water, not fat
5:33 Cortisol: about 1 percent of the difference
7:10 PCOS is now PMOS
9:04 Menopause and the pattern across every hormone
Resources
Barbell Medicine coaching and templates: barbellmedicine.com
Plus podcast subscription: barbellmedicine.com/shop/subscriptions/plus-podcast-subscription
Barbell Medicine Premium: barbellmedicine.com/shop/subscriptions/barbell-medicine-premium
Signal (book pre-order): barbellmedicine.com/shop/learning/signal
Metabolism
Pontzer et al., Science 2021. doi.org/10.1126/science.abe5017
Muller et al., American Journal of Clinical Nutrition 2015. doi.org/10.3945/ajcn.115.109173
Lichtman et al., New England Journal of Medicine 1992. doi.org/10.1056/NEJM199212313272701
Hormones
Karmisholt et al., Journal of Clinical Endocrinology and Metabolism 2011. doi.org/10.1210/jc.2010-1521
Lee et al., Endocrine Practice 2014. doi.org/10.4158/EP14072.OR
van der Valk et al., Obesity Reviews 2022. doi.org/10.1111/obr.13376
Nikokavoura et al., Diabetes, Metabolic Syndrome and Obesity 2015. doi.org/10.2147/DMSO.S85134
Greendale et al., JCI Insight 2019. doi.org/10.1172/jci.insight.124865
Also referenced: the PCOS-to-PMOS renaming (The Lancet consensus, 2026) and the American Thyroid Association patient guidance on thyroid weight.








![The FDA Voted for 6 Peptides. Its Own Scientists Said No
An FDA advisory committee just voted to open a legal compounding supply line for six of seven peptides, including BPC-157 and TB-500, over the objection of the FDAs own scientists, who recommended against all seven. Dr. Jordan Feigenbaum walks through what the Pharmacy Compounding Advisory Committee actually voted on, why a vote about ulcerative colitis ends up governing tendon and joint use, what the single human BPC-157 trial does and doesnt show, and why a pharmacy makes it safe and theres no money to study it dont hold up. Evidence-based, no hype, no nocebo.
Timestamps:
| 00:00:00 | The FDA voted 8-6. What it actually means
| 00:01:25 | What I am, and am not, claiming
| 00:03:21 | How they got here: Category 2 and the paperwork
| 00:07:17 | Who was in the room: the panel that flipped
| 00:10:57 | What they voted on: compounding and the bulks list
| 00:15:37 | No money in it, you cant patent it
| 00:18:24 | The trials already run: Plevna and MK-677
| 00:22:55 | I took it and it worked: placebo and fake surgery
| 00:27:02 | The one human trial: Ruenzi 2005
| 00:32:28 | Is it natural? Is it even a drug?
| 00:36:58 | Harm reduction, or follow the money?
| 00:42:45 | Three times a missing trial went wrong
| 00:50:58 | Safety: known, unknown, and unknowable
| 00:55:22 | The other six peptides
| 00:58:22 | What Id actually tell you
| 01:02:08 | What actually works, and what would change my mind
Resources:
• Barbell Medicine coaching and templates: https://www.barbellmedicine.com
• Plus podcast subscription: https://www.barbellmedicine.com/shop/subscriptions/plus-podcast-subscription/
• Barbell Medicine Premium: https://www.barbellmedicine.com/shop/subscriptions/barbell-medicine-premium/
• Signal (book pre-order): https://www.barbellmedicine.com/shop/learning/signal/
1. US Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee Meeting. July 23-24, 2026. Silver Spring, MD: FDA; 2026.
2. US Food and Drug Administration. FDA review of BPC-157-related bulk drug substances. PCAC Briefing Document. July 23-24, 2026. Media 193343. Accessed July 24, 2026. https://www.fda.gov/media/193343/download
3. US Food and Drug Administration. FDA review of TB-500-related bulk drug substances. PCAC Briefing Document. July 23-24, 2026. Media 193349.
4. US Food and Drug Administration. FDA review of KPV-, MOTS-c-, Semax-, Epitalon-, and Emideltide-related bulk drug substances. PCAC Briefing Documents. July 23-24, 2026.
5. US Food and Drug Administration. Questions for the Pharmacy Compounding Advisory Committee. July 23-24, 2026.
6. US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting roster. July 23-24, 2026. Media 193772.
7. US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting roster. 2022. Media 159040.
8. openFDA. FAERS adverse event reports for BPC-157. Accessed July 24, 2026. https://open.fda.gov
9. Pharmacy compounding; 503A bulk drug substances. 21 CFR §216.23 (2026).
10. Federal Food, Drug, and Cosmetic Act §503A, 21 USC §353a (pharmacy compounding).
11. Abigail Alliance for Better Access to Developmental Drugs v von Eschenbach, 495 F3d 695 (DC Cir 2007).
12. United States v Rutherford, 442 US 544 (1979).
13. Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, Pub L No. 115-176, 132 Stat 1372 (2018).
14. US Food and Drug Administration. Regulatory considerations for human drug products containing peptides. Guidance for Industry (draft). 2020.
15. Ruenzi M, Stolte M, Veljaca M, et al. Efficacy and safety of PL 14736 (BPC 157) in patients with active ulcerative colitis [abstract]. Gastroenterology. 2005. Meeting abstract; full study not published.
16. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-1117. doi:10.1002/jor.20089
17. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
18. Sikiric P, Skrtic A, Gojkovic S, et al. Stable gastric pentadecapeptide BPC 157 and hemorrhage/thrombosis. Pharmaceuticals (Basel). 2026;19(3):463. doi:10.3390/ph19030463
19. Stavchansky VV, Filippenkov IB, Dergunova LV, Limborska SA. The role of glyprolines in the regulation of gene expression: focus on Semax. Genes (Basel). 2022;13(12):2380. doi:10.3390/genes13122380
20. Mendias CL, Awan TM. The safety and efficacy of approved and unapproved peptides. Sports Med. 2026. doi:10.1007/s40279-026-02437-0
21. Moseley JB, OMalley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347(2):81-88. doi:10.1056/NEJMoa013259
22. Cobb LA... The FDA Voted for 6 Peptides. Its Own Scientists Said No](https://i.ytimg.com/vi/KwPlmH8HORg/mqdefault.jpg)

